Looking at top Wall Street opinions, CVS Health Corporation (NYSE: CVS) has recently made its way into the research list of Standpoint Research – signaling that their analyst’s rating adjustment is noteworthy. This stock was upgraded to a rating of Buy in the eyes of Standpoint Research, whereas its previous rating was Hold in the eyes of Standpoint Research, as reported on Wednesday, June 5th, 2019. Another heavy-hitting research note was published by Credit Suisse on Monday April 29th, 2019, with this firm downgrading CVS to an updated rating of Neutral from its previous rating of Outperform. In the past six months and three months of trading, shares of CVS Health Corporation (CVS) have moved by 0.16% and 17.54%, respectively.
Brokerage Updates Related to CVS Health Corporation (CVS) Stock
This publicly-traded organization generated gains of 5.46% over the last 5 sessions. Right now, this stock is the subject of 26 analysts’ evaluations, who – on average – have given this company’s shares a Buy rating. Not a Single analyst have given underperform rating or sell rating, and 7 have given a rating of Buy or better. Based on the 26 stock market experts following this company, the average 12-month price target is $68.27. Moreover, individual price targets range between $58.00-$88.00. With its recent move to $71.00, we can see that these firms project this stock will loss by -15.80% in one year.
Updates from CVS Health Corporation (CVS) SEC Form 4
This particular company’s shares have garnered a lot of attention in recent days, as insiders are unloading their holdings while having generated a 0.10% rise since the beginning of the calendar year. A Director at CVS Health Corporation (CVS) bought some of its shares in a transaction that was finalized on Mar 11. Similarly, AGUIRRE FERNANDO bought 1,900 shares of the organization’s stock at $53.59 apiece and racked up $101,821 in earnings from the purchase. Now, AGUIRRE FERNANDO holds 16,222 shares of the company following the exchange. A Director of the organization named LUDWIG EDWARD J, was engaged in a transaction that occurred on Mar 08 that managed to be worth $105,600 from the purchase of 2,000 common shares at a price of $52.80 per individual share.
CVS Health Corporation (NYSE:CVS) Results in the Pipeline
The next scheduled release of financial results for CVS Health Corporation will be for the Jun-19 quarter. As it stands right now, market analysts are anticipating the per-share earnings for the three-month period will be $1.69. In the same vein, they expect sales for the quarter to amount to $62,650.90 million.
Now let’s turn to earnings surprise history: in the most recent quarter, the company reported about $63,431.00 million in revenue alongside EPS at $1.89. On average, the analyst projection was calling for $61,646.00 million with $1.62 per share in earnings, respectively. In the preceding quarter, this company’s revenue reached $54,424.00 million, with earnings per share ending up at $2.14.
The Southern Company (NYSE:SO) experienced a gain of 0.86% from the closing price in the previous trading day. That boost the price to $58.45 per share, as observed on January 1st, 1970, at a time when the total trading volume reached 4,362,133 shares of stock – compared to the typical average of 4.41M shares per day (as recorded over the past three months). The consensus estimate for these shares has been shifted to $56.47.
Pricing Indications for The Southern Company (SO)
This organization has had a price-to-earnings ratio of 13.85 in the last year. Meanwhile, it gained 56.36 from its observable 50-day simple moving average. Right at this moment, the per-share value is 14.00% higher than the mean per-share price over the last 200 days in the market.
The Southern Company (NYSE:SO) In-Depth Brokerage Insights
We can see that a number of brokerage firms are putting their focus onto this stock. Out of this group, 1 have a sell rating, 0 have a Buy rating, 2 have an outperform rating, while 12 provided a Hold rating for these shares – thanks to data from Thomson Reuters I/B/E/S. Additionally, 4 have recommended that these shares are an Underperforming investment. The current consensus recommendation is at 3.20 , based on information from Thomson Reuters.
SO Stock Value Potential
In trading activity as of late, this stock’s value was 51.34 up from its 200 day moving average, while also 3.83% up when compared against its 50-day simple moving average. Over the course of the past year of trading, the share price stuck in the range of $52.00-$61.00. The market value for the entire organization reached 61.25B. In the last trading session, the price ended the day at $57.95. The institutional holdings related to this organization account for 0.08%, and the Beta factor is now 0.16. This company’s RSI (Relative Strength Index) managed to hit 60.44.
The Southern Company (NYSE:SO) Analyst Points of Focus
The Southern Company (SO) has found itself inside of Evercore ISI’s research list, so their analyst rating adjustment is worth taking note of. This stock was upgraded to In-line, compared to its previous rating of Underperform by Evercore ISI, as garnered from a news report on Friday February 22nd, 2019. An additional helpful research note was sent out by Citigroup’s on Thursday January 24th, 2019. The brokerage decided to upgrade SO to Neutral from its previous rating of Sell.